Randomized Phase III Trial Comparing an Association of Hormonal Treatment and Docetaxel Versus the Hormonal Treatment Alone in Metastatic Prostate Cancers
Overview
- Phase
- Phase 3
- Intervention
- orchiectomy
- Conditions
- Prostate Cancer
- Sponsor
- UNICANCER
- Enrollment
- 385
- Locations
- 41
- Primary Endpoint
- Treatment costs
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as goserelin, may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving hormone therapy together with docetaxel may be an effective treatment for prostate cancer. It is not yet known whether giving hormone therapy together with docetaxel is more effective than hormone therapy alone in treating prostate cancer.
PURPOSE: This randomized phase III trial is studying hormone therapy and docetaxel to see how well they work compared to hormone therapy alone in treating patients with metastatic prostate cancer.
Detailed Description
OBJECTIVES: * Compare 36-month overall survival of patients with metastatic prostate adenocarcinoma treated with hormonal therapy and docetaxel vs hormonal therapy alone. * Compare 24-month progression-free survival (biological progression and/or clinical progression) in patients treated with these regimens. * Compare the quality of life of patients treated with these regimens. * Compare costs of these regimens for these patients. * Compare the tolerability of these regimens in these patients. * Compare the toxicity profile of these regimens in these patients. OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive hormonal therapy comprising 1 of the following: goserelin alone OR goserelin and antiandrogen therapy OR surgical castration. Hormonal therapy continues until the development of hormone resistance. Within 2 months after initiation of hormonal therapy, patients receive docetaxel IV every 3 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity. * Arm II: Patients receive hormonal therapy as in arm I. Quality of life is assessed. PROJECTED ACCRUAL: A total of 378 patients will be accrued for this study.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Hormonotherapy + chemotherapy
Intervention: orchiectomy
Hormonotherapy + chemotherapy
Intervention: antiandrogen therapy
Hormonotherapy + chemotherapy
Intervention: docetaxel
Hormonotherapy + chemotherapy
Intervention: goserelin acetate
Hormonotherapy alone
Intervention: antiandrogen therapy
Hormonotherapy alone
Intervention: goserelin acetate
Hormonotherapy alone
Intervention: orchiectomy
Outcomes
Primary Outcomes
Treatment costs
Toxicity and tolerance
Overall survival at 36 months
Tumor profiles of gene expression as measured by biochips with DNA and tissue microarrays
Progression-free survival (biological progression and/or clinical progression) at 24 months
Quality of life